CA2662473A1 - Medical devices having nanostructured coating for macromolecule delivery - Google Patents
Medical devices having nanostructured coating for macromolecule delivery Download PDFInfo
- Publication number
- CA2662473A1 CA2662473A1 CA002662473A CA2662473A CA2662473A1 CA 2662473 A1 CA2662473 A1 CA 2662473A1 CA 002662473 A CA002662473 A CA 002662473A CA 2662473 A CA2662473 A CA 2662473A CA 2662473 A1 CA2662473 A1 CA 2662473A1
- Authority
- CA
- Canada
- Prior art keywords
- medical device
- macromolecules
- nanoparticles
- phosphate
- coating
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L27/58—Materials at least partially resorbable by the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
- A61L27/28—Materials for coating prostheses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/08—Materials for coatings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
- A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
- A61L31/148—Materials at least partially resorbable by the body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2400/00—Materials characterised by their function or physical properties
- A61L2400/12—Nanosized materials, e.g. nanofibres, nanoparticles, nanowires, nanotubes; Nanostructured surfaces
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2420/00—Materials or methods for coatings medical devices
- A61L2420/04—Coatings containing a composite material such as inorganic/organic, i.e. material comprising different phases
Abstract
A medical device having a biodegradable coating comprising an inorganic material complexed to macromolecules. Biodegradation of the biodegradable coating releases nanoparticles of the inorganic material with macromolecules complexed to the released nanoparticles. The inorganic material may be applied directly onto the medical device as a nanostructured coating or be dispersed within or under a layer of biodegradable polymer. The medical device body may comprise a biodegradable metallic material. Also provided is a method of delivering macromolecules to body tissue using the medical device of the present invention.
Description
MEDICAL DEVICES HAVING NANOSTRUCTURED
COATING FOR MACROMOLECULE DELIVERY
TECHNICAL FIELD
100011 T'he present invention relates to coated medical devices. More specifically, the present invention relates to niedical devices having a nanostructured coating for carrying and releasing niacromolecules.
BACKGROUND
(00021 Many implantable medical devices have a drug-loaded coating designed to improve the effectiveness of the medical device. For example, some coronary artery stents are coated with a drug kvliicli is eluted from the stent to prevent some of the unwanted effects and complications of implanting the stent. Some have also attempted to use medical device coatings as a means to provide gene therapy. For example, some investigators have used stents with a coating that elutes naked DNA encoding human vascular endothelial growth factor (VEGF-2) to treat cells in the arterial wall. Naked DNA, however, is not an efficient means for transfecting cells. See Scllmidt-Wolf et al., Trends in Molecular Medicine 9(2):67-72 (2003), which is incorporated by reference herein. Thus, there is a need for a medical device that delivers macromolecules, such as DNA, more effectively to tissue cells.
SUMMARY OF THE INVENTION
[0003] The present invention is directed to a medical device that provides a tneans of delivering macromolecules. In an embodiment, the present invention provides a medical device comprising a medical device, body, such as a stent; a biodegradable coating comprising an inorganic material disposed on the medical device body; and macromolecules conjugated to the inorganic material; wherein biodegradation of the coating releases nanoparticles of the inorganic material, and wherein the macromolecules are conjugated to the released nanoparticles. In an embodiment, the inorganic material forms a nanostructured layer. The inorganic materials may comprise metal salts, metal oxides, or- metal hydroxides. The macromolecules may be conjugated to the exterior or interior of the nanoparticles by ionic bonding.
The macromolecules may be polynucleotides. The nanoparticles may be released individually or in aggregates. The biodegradable coating may further comprise a buffering agent.
[00041 In another embodiment of the present invention, the biodegradable coating further comprises a biodegradable polymer. In yet another embodiment, the medical device body (e.g., a stent) comprises a biodegradable metallic material, and the inorganic material comprises metal pllosphates. Biodegradation of the metallic material can release metal ions and biodegradation of the coating can release phosphate ions such that the metal ions and phosphate ions combine to form metal phosphate nanoparticles, and wherein macromolecules are conj ugated to the metal phosphate nanoparticles. Biodegradation of the metallic material can involve a corrosive process and the coating may modulate the corrosive process. Ttie coating and the medical device body -can form a galvanic couple.
[00051 The present invention also provides a method of delivering macromolecules to body tissue comprising the steps of providing a medical device of the present invention and implanting the medical device in a subject's body.
BRIEF DESCRIPTION OF THE DRAWINGS
100061 Fig. I is a high magnification view of an exeniplary nanostructured coating.
[00071 Fig. 2 show nanoparticles according to an embodiment of the present invention and a schematic,representation of the transfection mechanism.
[00081 Fig. 3'shows an aggregate of nanoparticles according to an alternate embodiment of the present invention.
DETAILED DESCRIPTION
[0009) The present ihvention provides a medical device having a biodegradable eoating comprising an inorganic material complexed to macromolecules. Biodegradation of the biodegradable coating releases nanoparticles of the inorganic material with,macromolecules complexed to the released nanoparticles_ (00101 In an embodiment of the present invention, the inorganic material is applied directly onto the medical device as a nanostructured coating. Nanostructures of the present invention include structures having at least one characteristic domain with a dimension in the nanometer range, such as 500 nm or less. The domain dimension may be along the largest or smallest axis of the structure. The domains may be any physical feature or eterrient of the nanostructure, such as pores, matrices, particles; or grains. Biodegradability of any material of the present invention includes the process of breaking down or degrading by either chemical, including corrosive, or physical processes upon interaction with a physiological environment. The products of the degradation proccss may be soluble, such as metal cations, or insoluble precipitates. Insoluble precipitates may form particles, such as metal phosphate nanopartictes.
100111 The inorganic material is biocompatible and may be a metal salt, metal oxide, or metal hydroxide. The metal may be a metal in which its cation forms ionic complexes with DNA, such as Ca2*, Mg2+, Mna}, or Baa". The inorganic material may also be an inorganic phosph'ate or a metal phosphate such as magnesium phosphate, manganese phospllate, barium phosphate, calciurri phosphate, or mixtures or combinations of these, such as calcium-magnesium phosphate.
[00121 The inorganic material is applied to the medical device by any known method of deposition that forms a nanostructured coating. These methods can include sol-gel, layer-by-layer (LbL) coating, self-assembly, chemical or physical vapor deposition, or spraying. The nanostructured coating.can also be formed by the method described in Kouisni et al., Surface Coating & Technology 192:239-246 (2005); which is incorporated by reference herein. Kouisni describes creating a zinc phosphate coating on magnesium alloy AM60 (containing 6% Al and G.28% Mn) by immersing the alloy in a 3.0 pH phosphating bath containing phosphoric acid, phosphate ions, nitrates, nitrites, zinc, and fluorides.
[0013] Fig. I shows a high magnification view of an exemplary nanostructured coating (image obtained from Sol-Gel Technologies) that can be created by soi-gel techniques for use with the present invention. In this particular example, the characteristics domains of the nanostructure are.nanaparticies which range in size from about 30 to about 45 nm in diameter.
This example is provided merely to illustrate and is not intended to be limiting.
[0014] Macromolecules are conjugated to the inorganic material by ionic bonding. The macromolecules can include, for eXample, polynucleotides, peptides, proteins, enzymes, polyainines, polyamine acids, polysaccharides, lipids, as well as small molecule compounds such as pharmaceuti,cals. The polynucleotides may be DNA or RNA, which can encode a variety of proteins or polypeptides, and the potynucleotides may be inserted into recombinant vectors such as plasmids, cosmids, phagemids, phage, viruses, and the like. There is no limit to the size of the polynucleotides, as described in Schmidt-Wolf et al., Trends in Molecular Medicine 9(2):67-72 (2003), which is incorporated by reference herein. The macromolecules may be attached to the external surface of the nanostructure domains, incorporated or dispersed within the nanostructure domains, or within the matrix of the nanostructure.
100151 After the medical device is implanted in the subject's body and exposed to a physiologic environment, the nanostructured coating undergoes biodegradation.
Biodegradation of the nanostructured coating may be a physical process, such as the frictional and mechanical forces created by the flow of fluid or blood. The biodegradation may also'be a chemical process, such as corrosion or hydrolysis.
[00161 Referring to Fig. 2, biodegradation of the nanostructured coating results in the release of nanoparticles 30 of the inorganic material into the surrounding fluid or tissue. In an embodiment, macromolecules 20 are conjugated to the surface of nanoparticles 30. In an alternate embodimcnt, macromolecules 20 are incorporated or dispersed within nanoparticle 30, or encapsulated within nanoparticle 30, as described in Bhakta et al., Biomaterials 26:2157-2163 (2005), which is incorporated by referencc herein. The nanoparticles may be released individually or in.aggregates, as shown in Fig. 3, such that the aggregates themselves are nanoparticles. The nanoparticles are of sizes that allow them to serve as,polynucleotide vectors in cell transfection. For example, inorganic calcium-magnesium phosphate nanoparticles of up to 500 nm have been shown to be effective in gene transfection of Hela and NIH-3T3 cells, as described in Chowdhury et al., Gene 341:77-82 (2004), which is incorporated by reference herein.
100171 The present invention provides a medical device coated with DNA-loaded nanoparticles that can be more effective in DNA transfection than naked DNA.
In particular, nanoparticles of calcium phosphate, calcium-magnesium phosphate, manganese phosphate, and magnesium phosphate have been demonstrated to be effective vectors for plasmid DNA
transfection into cells, as described in Bhakta et al., Biomaterials 26:2157-63 (2005);
Chowdhury et al., Gene 341:77-82 (2004); and U.S. Patent No. 6,555,376 (Maitra et al.), all of which are incorporated by reference herein. Referring again to Fig. 2 and without being bound by theory, it is believed that DNA-loaded nanoparticies 30 enter a cell 40 through the process of endocytosis. 'Inside the cell 40, the nanoparticles 30 are stored in endosomes 42 wherein the mildly acidic pH causes the DNA to be released from the nanoparticles.
[0018] One example of a medical device that can be coated with the nanostructured inorganic material of the present invention is a stent. Plasmid DNA encoding for genes that can be used to treat vascular diseases and conditions, such as the gene for hunian vascular endothelial growth factor-2 (VEGF-2), can be conjugated to the inorganic material. DNA-carrying nanoparticles released from the coating can be taken up by cells in the vascular wall tluough endocytosis or any other transfection mechanism.
100191 In another embodiment of the present invention, the body of the medical device is formed oCa biodegradable metallic material, such as the metal alloys used in the biodegradable coronary stents described in U.S. Patent No. 6,287,332 (Bolz et al.), which is incorporated by reference herein. In these embodiments, the body of the implanted medical device will biodegrade into harmless constituents inside the subject's body. The biodegradation may involve a corrosive process.
[0020,1 Cn this embodiment, a nanostructured coating comprising a metal phosphate material is disposed on the medical device body and macromolecules are conjugated to the metal phosphate material. As in previous embodiments, biodegradation of the nanostructured coating results in the release of nanoparticles, wherein macromolecules are conjugated to the nanoparticles. In this embodiment, nanoparticles can also be formed by the recombination of metal ions resulting from the biodegradation of the medical device body and phosphate ions resulting from the biodegradation of the metal phosphate coating. The metal ions combined with phosphate ions can precipitate into nanoparticles wherein macromolecules are conjugated to the nanoparticles, as described in Haberland et al., Biochirnica et Biophysica Act 1445:21-30 (1999), which is incorporated by reference herein.
[00211 Phosphate coatings on metal substrates are known to slow the-corrosion of the underlying metal. Examples of such phosphate coatings include coatings formed of zinc phosphate, manganese phosphate, calcium phosphate, and iron phosphate, as described in Weng et al., Surface Coating & Technology 88:147-156 (1996), which is incorporated by reference herein. Thus, in this embodiment, the metal phosphate coating can be used to alter the corrosion rate of the underlying medical device body, in addition to serving as a delivery system for macromolecules.
[00221 The corrosion rate of the medical device body will vary,with the composition, thickness, porosity, electrochemical properties, and mechanical properties of the inorganic phosphate coating. Therefore, one of skill in the art can adjust such factors to achieve the desired corrosion rate in the medical device body. For example, it may be desirable to slow the corrosion rate where an extended period of mechanical stability is required for effective functioning of the medical device, such as a stent supporting a vascular wall.
lt may also be desirable to sloxv the corrosion rate to reduce the amount of harmful gases, insoluble precipitates, or other by-products generated by the corrosion process. In otlier cases, it may be desirable to accelerate the corrosion process.
100231 Where the coating and the medical device are formed of different metals, the two components may also fortn a galvanic couple, wherein electrical current is generated between the coating and medical device body with the surrounding fluid or tissue serving as the electrolyte.
For example, a galvanic current may be generated between a coating formed of zinc and zinc phosphate and a medical device formed of magnesium. Ttie galvanic current will alter the corrosion rate of the metal components of the coating or medical device.
Furthermore, it is known that the application of electrical current to cells can improve DNA
transfection, as described in Schmidt-Wolf et al., Trends in Molecular Medicine 9(2):67-72 (2003), wliich is incorporated by reference 'herein. Thus, the current generated by the galvanic coupling of the coating and medical device body may also be used to enhance DNA transfection.
100241 In another embodiment of the present invention, the biodegradable coating further comprises a layer of biodegradable polymer, wherein the inorganic material with macromolecules complexed thereto is dispersed within or under the layer of biodegradable polymer. Upon implantation of the medical device, the biodegradable polymer layer is degraded by exposure to a physiologic environment, releasing the inorganic material and macromolecules.
100251 In certain embodiments, the biodegradable coating may further comprise an electrically conductive polymer such as phosphate-doped polypyrrole. The electrically conductive polymer can form a galvanic couple with a substrate metallic medical device, and thereby control the corrosion rate of the medical device.
100261 In certain embodiments, the coating may further comprise a buffering agent which would serve to control the pH of the local environment surrounding the medical device. For example, formation of buffer coatings on medical devices using ion-exchange resins is described in U.S. Patent No. 5,941,843 (Atanasoska et al.), which is incorporated by reference herein. The buffering agent inay be used to reduce the pH within or adjacent to the coating to increase the dissolution of the inorganic material. See Bhakta et al., Biornaterials 26:2157-63 (2005), which is incorporated by reference herein.
(0027) The medical device of the present invention is not limited to the coronary stents in the disclosed embodirnents. Non-limiting exacnples of other medical devices that can be used with the nanostructured coating of the present invention include catheters, guide wires, balloons, filters (e.g., vena cava filters), stents, stent grafts, vascular grafts, intraluminal paving systems, pacemakers, electrodes, leads, defibrillators, joint and bone irnplants, spinal implants, vascular access ports, intra-aortic balloon pumps, heart valves, sutures, artificial hearts, neurological stimulators, eoehlear implants, retinal implants, and other devices that can be. used in connection with therapeutic coatings. Such medical devices are iniplanted or othenvise used in body structures or cavities such as the vasculature, gastrointestinal tract, abdomen, peritoneum, airways, esophagus, trachea, colon, rectum, biliary tract, urinary tract, prostate, brain, spine, lung,'liver, heart, skeletal muscle, kidney, bladder, intestines, stomach, pancreas, ovary, uterus, cartilage, eye, bone, and the like.
[00281 The foregoing description and examples have been set forth merely to illustrate the invention and are not intended to be limiting. Each of the disclosed aspects and embodiments of the present invention may be considered individually or in combination with other aspects, embodiments, and variations of the invention. In addition, unless otherwise specified, none of the steps of the methods of the present invention are confined to any particular order of performance. Modifications of the disclosed embodiments incorporating the spirit and substance of the invention may occur to persons skilled in the art and such modifications are within.the scope of the present invention. Furthermore, all references cited herein are incorporated by reference in their entirety.
COATING FOR MACROMOLECULE DELIVERY
TECHNICAL FIELD
100011 T'he present invention relates to coated medical devices. More specifically, the present invention relates to niedical devices having a nanostructured coating for carrying and releasing niacromolecules.
BACKGROUND
(00021 Many implantable medical devices have a drug-loaded coating designed to improve the effectiveness of the medical device. For example, some coronary artery stents are coated with a drug kvliicli is eluted from the stent to prevent some of the unwanted effects and complications of implanting the stent. Some have also attempted to use medical device coatings as a means to provide gene therapy. For example, some investigators have used stents with a coating that elutes naked DNA encoding human vascular endothelial growth factor (VEGF-2) to treat cells in the arterial wall. Naked DNA, however, is not an efficient means for transfecting cells. See Scllmidt-Wolf et al., Trends in Molecular Medicine 9(2):67-72 (2003), which is incorporated by reference herein. Thus, there is a need for a medical device that delivers macromolecules, such as DNA, more effectively to tissue cells.
SUMMARY OF THE INVENTION
[0003] The present invention is directed to a medical device that provides a tneans of delivering macromolecules. In an embodiment, the present invention provides a medical device comprising a medical device, body, such as a stent; a biodegradable coating comprising an inorganic material disposed on the medical device body; and macromolecules conjugated to the inorganic material; wherein biodegradation of the coating releases nanoparticles of the inorganic material, and wherein the macromolecules are conjugated to the released nanoparticles. In an embodiment, the inorganic material forms a nanostructured layer. The inorganic materials may comprise metal salts, metal oxides, or- metal hydroxides. The macromolecules may be conjugated to the exterior or interior of the nanoparticles by ionic bonding.
The macromolecules may be polynucleotides. The nanoparticles may be released individually or in aggregates. The biodegradable coating may further comprise a buffering agent.
[00041 In another embodiment of the present invention, the biodegradable coating further comprises a biodegradable polymer. In yet another embodiment, the medical device body (e.g., a stent) comprises a biodegradable metallic material, and the inorganic material comprises metal pllosphates. Biodegradation of the metallic material can release metal ions and biodegradation of the coating can release phosphate ions such that the metal ions and phosphate ions combine to form metal phosphate nanoparticles, and wherein macromolecules are conj ugated to the metal phosphate nanoparticles. Biodegradation of the metallic material can involve a corrosive process and the coating may modulate the corrosive process. Ttie coating and the medical device body -can form a galvanic couple.
[00051 The present invention also provides a method of delivering macromolecules to body tissue comprising the steps of providing a medical device of the present invention and implanting the medical device in a subject's body.
BRIEF DESCRIPTION OF THE DRAWINGS
100061 Fig. I is a high magnification view of an exeniplary nanostructured coating.
[00071 Fig. 2 show nanoparticles according to an embodiment of the present invention and a schematic,representation of the transfection mechanism.
[00081 Fig. 3'shows an aggregate of nanoparticles according to an alternate embodiment of the present invention.
DETAILED DESCRIPTION
[0009) The present ihvention provides a medical device having a biodegradable eoating comprising an inorganic material complexed to macromolecules. Biodegradation of the biodegradable coating releases nanoparticles of the inorganic material with,macromolecules complexed to the released nanoparticles_ (00101 In an embodiment of the present invention, the inorganic material is applied directly onto the medical device as a nanostructured coating. Nanostructures of the present invention include structures having at least one characteristic domain with a dimension in the nanometer range, such as 500 nm or less. The domain dimension may be along the largest or smallest axis of the structure. The domains may be any physical feature or eterrient of the nanostructure, such as pores, matrices, particles; or grains. Biodegradability of any material of the present invention includes the process of breaking down or degrading by either chemical, including corrosive, or physical processes upon interaction with a physiological environment. The products of the degradation proccss may be soluble, such as metal cations, or insoluble precipitates. Insoluble precipitates may form particles, such as metal phosphate nanopartictes.
100111 The inorganic material is biocompatible and may be a metal salt, metal oxide, or metal hydroxide. The metal may be a metal in which its cation forms ionic complexes with DNA, such as Ca2*, Mg2+, Mna}, or Baa". The inorganic material may also be an inorganic phosph'ate or a metal phosphate such as magnesium phosphate, manganese phospllate, barium phosphate, calciurri phosphate, or mixtures or combinations of these, such as calcium-magnesium phosphate.
[00121 The inorganic material is applied to the medical device by any known method of deposition that forms a nanostructured coating. These methods can include sol-gel, layer-by-layer (LbL) coating, self-assembly, chemical or physical vapor deposition, or spraying. The nanostructured coating.can also be formed by the method described in Kouisni et al., Surface Coating & Technology 192:239-246 (2005); which is incorporated by reference herein. Kouisni describes creating a zinc phosphate coating on magnesium alloy AM60 (containing 6% Al and G.28% Mn) by immersing the alloy in a 3.0 pH phosphating bath containing phosphoric acid, phosphate ions, nitrates, nitrites, zinc, and fluorides.
[0013] Fig. I shows a high magnification view of an exemplary nanostructured coating (image obtained from Sol-Gel Technologies) that can be created by soi-gel techniques for use with the present invention. In this particular example, the characteristics domains of the nanostructure are.nanaparticies which range in size from about 30 to about 45 nm in diameter.
This example is provided merely to illustrate and is not intended to be limiting.
[0014] Macromolecules are conjugated to the inorganic material by ionic bonding. The macromolecules can include, for eXample, polynucleotides, peptides, proteins, enzymes, polyainines, polyamine acids, polysaccharides, lipids, as well as small molecule compounds such as pharmaceuti,cals. The polynucleotides may be DNA or RNA, which can encode a variety of proteins or polypeptides, and the potynucleotides may be inserted into recombinant vectors such as plasmids, cosmids, phagemids, phage, viruses, and the like. There is no limit to the size of the polynucleotides, as described in Schmidt-Wolf et al., Trends in Molecular Medicine 9(2):67-72 (2003), which is incorporated by reference herein. The macromolecules may be attached to the external surface of the nanostructure domains, incorporated or dispersed within the nanostructure domains, or within the matrix of the nanostructure.
100151 After the medical device is implanted in the subject's body and exposed to a physiologic environment, the nanostructured coating undergoes biodegradation.
Biodegradation of the nanostructured coating may be a physical process, such as the frictional and mechanical forces created by the flow of fluid or blood. The biodegradation may also'be a chemical process, such as corrosion or hydrolysis.
[00161 Referring to Fig. 2, biodegradation of the nanostructured coating results in the release of nanoparticles 30 of the inorganic material into the surrounding fluid or tissue. In an embodiment, macromolecules 20 are conjugated to the surface of nanoparticles 30. In an alternate embodimcnt, macromolecules 20 are incorporated or dispersed within nanoparticle 30, or encapsulated within nanoparticle 30, as described in Bhakta et al., Biomaterials 26:2157-2163 (2005), which is incorporated by referencc herein. The nanoparticles may be released individually or in.aggregates, as shown in Fig. 3, such that the aggregates themselves are nanoparticles. The nanoparticles are of sizes that allow them to serve as,polynucleotide vectors in cell transfection. For example, inorganic calcium-magnesium phosphate nanoparticles of up to 500 nm have been shown to be effective in gene transfection of Hela and NIH-3T3 cells, as described in Chowdhury et al., Gene 341:77-82 (2004), which is incorporated by reference herein.
100171 The present invention provides a medical device coated with DNA-loaded nanoparticles that can be more effective in DNA transfection than naked DNA.
In particular, nanoparticles of calcium phosphate, calcium-magnesium phosphate, manganese phosphate, and magnesium phosphate have been demonstrated to be effective vectors for plasmid DNA
transfection into cells, as described in Bhakta et al., Biomaterials 26:2157-63 (2005);
Chowdhury et al., Gene 341:77-82 (2004); and U.S. Patent No. 6,555,376 (Maitra et al.), all of which are incorporated by reference herein. Referring again to Fig. 2 and without being bound by theory, it is believed that DNA-loaded nanoparticies 30 enter a cell 40 through the process of endocytosis. 'Inside the cell 40, the nanoparticles 30 are stored in endosomes 42 wherein the mildly acidic pH causes the DNA to be released from the nanoparticles.
[0018] One example of a medical device that can be coated with the nanostructured inorganic material of the present invention is a stent. Plasmid DNA encoding for genes that can be used to treat vascular diseases and conditions, such as the gene for hunian vascular endothelial growth factor-2 (VEGF-2), can be conjugated to the inorganic material. DNA-carrying nanoparticles released from the coating can be taken up by cells in the vascular wall tluough endocytosis or any other transfection mechanism.
100191 In another embodiment of the present invention, the body of the medical device is formed oCa biodegradable metallic material, such as the metal alloys used in the biodegradable coronary stents described in U.S. Patent No. 6,287,332 (Bolz et al.), which is incorporated by reference herein. In these embodiments, the body of the implanted medical device will biodegrade into harmless constituents inside the subject's body. The biodegradation may involve a corrosive process.
[0020,1 Cn this embodiment, a nanostructured coating comprising a metal phosphate material is disposed on the medical device body and macromolecules are conjugated to the metal phosphate material. As in previous embodiments, biodegradation of the nanostructured coating results in the release of nanoparticles, wherein macromolecules are conjugated to the nanoparticles. In this embodiment, nanoparticles can also be formed by the recombination of metal ions resulting from the biodegradation of the medical device body and phosphate ions resulting from the biodegradation of the metal phosphate coating. The metal ions combined with phosphate ions can precipitate into nanoparticles wherein macromolecules are conjugated to the nanoparticles, as described in Haberland et al., Biochirnica et Biophysica Act 1445:21-30 (1999), which is incorporated by reference herein.
[00211 Phosphate coatings on metal substrates are known to slow the-corrosion of the underlying metal. Examples of such phosphate coatings include coatings formed of zinc phosphate, manganese phosphate, calcium phosphate, and iron phosphate, as described in Weng et al., Surface Coating & Technology 88:147-156 (1996), which is incorporated by reference herein. Thus, in this embodiment, the metal phosphate coating can be used to alter the corrosion rate of the underlying medical device body, in addition to serving as a delivery system for macromolecules.
[00221 The corrosion rate of the medical device body will vary,with the composition, thickness, porosity, electrochemical properties, and mechanical properties of the inorganic phosphate coating. Therefore, one of skill in the art can adjust such factors to achieve the desired corrosion rate in the medical device body. For example, it may be desirable to slow the corrosion rate where an extended period of mechanical stability is required for effective functioning of the medical device, such as a stent supporting a vascular wall.
lt may also be desirable to sloxv the corrosion rate to reduce the amount of harmful gases, insoluble precipitates, or other by-products generated by the corrosion process. In otlier cases, it may be desirable to accelerate the corrosion process.
100231 Where the coating and the medical device are formed of different metals, the two components may also fortn a galvanic couple, wherein electrical current is generated between the coating and medical device body with the surrounding fluid or tissue serving as the electrolyte.
For example, a galvanic current may be generated between a coating formed of zinc and zinc phosphate and a medical device formed of magnesium. Ttie galvanic current will alter the corrosion rate of the metal components of the coating or medical device.
Furthermore, it is known that the application of electrical current to cells can improve DNA
transfection, as described in Schmidt-Wolf et al., Trends in Molecular Medicine 9(2):67-72 (2003), wliich is incorporated by reference 'herein. Thus, the current generated by the galvanic coupling of the coating and medical device body may also be used to enhance DNA transfection.
100241 In another embodiment of the present invention, the biodegradable coating further comprises a layer of biodegradable polymer, wherein the inorganic material with macromolecules complexed thereto is dispersed within or under the layer of biodegradable polymer. Upon implantation of the medical device, the biodegradable polymer layer is degraded by exposure to a physiologic environment, releasing the inorganic material and macromolecules.
100251 In certain embodiments, the biodegradable coating may further comprise an electrically conductive polymer such as phosphate-doped polypyrrole. The electrically conductive polymer can form a galvanic couple with a substrate metallic medical device, and thereby control the corrosion rate of the medical device.
100261 In certain embodiments, the coating may further comprise a buffering agent which would serve to control the pH of the local environment surrounding the medical device. For example, formation of buffer coatings on medical devices using ion-exchange resins is described in U.S. Patent No. 5,941,843 (Atanasoska et al.), which is incorporated by reference herein. The buffering agent inay be used to reduce the pH within or adjacent to the coating to increase the dissolution of the inorganic material. See Bhakta et al., Biornaterials 26:2157-63 (2005), which is incorporated by reference herein.
(0027) The medical device of the present invention is not limited to the coronary stents in the disclosed embodirnents. Non-limiting exacnples of other medical devices that can be used with the nanostructured coating of the present invention include catheters, guide wires, balloons, filters (e.g., vena cava filters), stents, stent grafts, vascular grafts, intraluminal paving systems, pacemakers, electrodes, leads, defibrillators, joint and bone irnplants, spinal implants, vascular access ports, intra-aortic balloon pumps, heart valves, sutures, artificial hearts, neurological stimulators, eoehlear implants, retinal implants, and other devices that can be. used in connection with therapeutic coatings. Such medical devices are iniplanted or othenvise used in body structures or cavities such as the vasculature, gastrointestinal tract, abdomen, peritoneum, airways, esophagus, trachea, colon, rectum, biliary tract, urinary tract, prostate, brain, spine, lung,'liver, heart, skeletal muscle, kidney, bladder, intestines, stomach, pancreas, ovary, uterus, cartilage, eye, bone, and the like.
[00281 The foregoing description and examples have been set forth merely to illustrate the invention and are not intended to be limiting. Each of the disclosed aspects and embodiments of the present invention may be considered individually or in combination with other aspects, embodiments, and variations of the invention. In addition, unless otherwise specified, none of the steps of the methods of the present invention are confined to any particular order of performance. Modifications of the disclosed embodiments incorporating the spirit and substance of the invention may occur to persons skilled in the art and such modifications are within.the scope of the present invention. Furthermore, all references cited herein are incorporated by reference in their entirety.
Claims (21)
1. A medical device, comprising:
(a) a medical device body;
(b) a biodegradable coating comprising an inorganic material disposed on the medical device body; and (c) macromolecules conjugated to the inorganic material;
wherein biodegradation of the coating releases nanoparticles of the inorganic material, and wherein the macromolecules are conjugated to the released nanoparticles.
(a) a medical device body;
(b) a biodegradable coating comprising an inorganic material disposed on the medical device body; and (c) macromolecules conjugated to the inorganic material;
wherein biodegradation of the coating releases nanoparticles of the inorganic material, and wherein the macromolecules are conjugated to the released nanoparticles.
2. The medical device of claim 1, wherein the inorganic material forms a nanostructured layer.
3. The medical device of claim 1, wherein the inorganic material comprises a metal salt, a metal oxide, or a metal hydroxide.
4. The medical device of claim 3, wherein the metal salt is selected from the group consisting of magnesium phosphate, calcium phosphate, calcium-magnesium phosphate, zinc phosphate, iron phosphate, barium phosphate, and manganese phosphate.
5. The medical device of claim 1, wherein the macromolecules are conjugated to the exterior of the nanoparticles.
6. The medical device of claim 1, wherein the macromolecules are conjugated to the interior of the nanoparticles.
7. The medical device of claim 1, wherein the nanoparticles are released in aggregates.
8. The medical device of claim 1, wherein the macromolecules are polynucleotides.
9. The medical device of claim 8, wherein the polynucleotides comprise a gene encoding for human vascular endothelial growth factor-2.
10. The medical device of claim 1, wherein the biodegradable coating further comprises a biodegradable polymer.
11. The medical device of claim 10, wherein the biodegradable coating further comprises an electrically conductive polymer.
12. The medical device of claim 1, wherein the biodegradable coating further comprises a buffering agent.
13. The medical device of claim 1, wherein the medical device body comprises a biodegradable metallic material.
14. The medical device of claim 13, wherein metal ions are released by biodegradation of the metallic material.
15. The medical device of claim 14, wherein phosphate ions are released by biodegradation of the coating.
16. The medical device of claim 15, wherein the metal ions and phosphate ions combine to form metal phosphate nanoparticles, and wherein the macromolecules are conjugated to the metal phosphate nanoparticles.
17. The medical device of claim 13, wherein biodegradation of the metallic material of the medical device body includes a corrosive process.
18. The medical device of claim 17, wherein the coating modulates the corrosion of the metallic material of the medical device body.
19. A method of delivering macromolecules to body tissue, comprising:
(i) providing a medical device, wherein the medical device comprises:
(a) a medical device body;
(b) a biodegradable coating comprising an inorganic material disposed on the medical device body; and (c) macromolecules conjugated to the inorganic material;
wlierein biodegradation of the coating releases nanoparticles of the inorganic material, and wherein the macromolecules are conjugated to the released nanoparticles; and (ii) implanting the medical device in a subject's body.
(i) providing a medical device, wherein the medical device comprises:
(a) a medical device body;
(b) a biodegradable coating comprising an inorganic material disposed on the medical device body; and (c) macromolecules conjugated to the inorganic material;
wlierein biodegradation of the coating releases nanoparticles of the inorganic material, and wherein the macromolecules are conjugated to the released nanoparticles; and (ii) implanting the medical device in a subject's body.
20. The method of claim 19, wherein the macromolecules are polynucleotides.
21. The method of claim 20, wherein the polynucleotides comprise a gene encoding for human vascular endothelial growth factor-2.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US84238306P | 2006-09-06 | 2006-09-06 | |
| US60/842,383 | 2006-09-06 | ||
| PCT/US2007/019092 WO2008030383A2 (en) | 2006-09-06 | 2007-08-30 | Medical devices having nanostructured coating for macromolecule delivery |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2662473A1 true CA2662473A1 (en) | 2008-03-13 |
Family
ID=39032173
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002662473A Abandoned CA2662473A1 (en) | 2006-09-06 | 2007-08-30 | Medical devices having nanostructured coating for macromolecule delivery |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20080057105A1 (en) |
| EP (1) | EP2068967A2 (en) |
| JP (1) | JP2010502362A (en) |
| CA (1) | CA2662473A1 (en) |
| WO (1) | WO2008030383A2 (en) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7727221B2 (en) | 2001-06-27 | 2010-06-01 | Cardiac Pacemakers Inc. | Method and device for electrochemical formation of therapeutic species in vivo |
| US7785615B2 (en) * | 2004-05-28 | 2010-08-31 | Cordis Corporation | Biodegradable medical implant with encapsulated buffering agent |
| US8840660B2 (en) | 2006-01-05 | 2014-09-23 | Boston Scientific Scimed, Inc. | Bioerodible endoprostheses and methods of making the same |
| US8089029B2 (en) | 2006-02-01 | 2012-01-03 | Boston Scientific Scimed, Inc. | Bioabsorbable metal medical device and method of manufacture |
| US8048150B2 (en) | 2006-04-12 | 2011-11-01 | Boston Scientific Scimed, Inc. | Endoprosthesis having a fiber meshwork disposed thereon |
| US8052743B2 (en) | 2006-08-02 | 2011-11-08 | Boston Scientific Scimed, Inc. | Endoprosthesis with three-dimensional disintegration control |
| EP2081616B1 (en) | 2006-09-15 | 2017-11-01 | Boston Scientific Scimed, Inc. | Bioerodible endoprostheses and methods of making the same |
| EP2068782B1 (en) | 2006-09-15 | 2011-07-27 | Boston Scientific Limited | Bioerodible endoprostheses |
| CA2663220A1 (en) | 2006-09-15 | 2008-03-20 | Boston Scientific Limited | Medical devices and methods of making the same |
| JP2010503491A (en) | 2006-09-15 | 2010-02-04 | ボストン サイエンティフィック リミテッド | Bioerodible endoprosthesis with biologically stable inorganic layers |
| US8002821B2 (en) | 2006-09-18 | 2011-08-23 | Boston Scientific Scimed, Inc. | Bioerodible metallic ENDOPROSTHESES |
| DE602007010669D1 (en) | 2006-12-28 | 2010-12-30 | Boston Scient Ltd | HREN FOR THIS |
| US8052745B2 (en) | 2007-09-13 | 2011-11-08 | Boston Scientific Scimed, Inc. | Endoprosthesis |
| DE202007015205U1 (en) * | 2007-10-05 | 2008-02-28 | Epple, Matthias, Prof. Dr. | implant |
| US8118857B2 (en) * | 2007-11-29 | 2012-02-21 | Boston Scientific Corporation | Medical articles that stimulate endothelial cell migration |
| US7998192B2 (en) | 2008-05-09 | 2011-08-16 | Boston Scientific Scimed, Inc. | Endoprostheses |
| US20090287301A1 (en) * | 2008-05-16 | 2009-11-19 | Boston Scientific, Scimed Inc. | Coating for medical implants |
| US8236046B2 (en) | 2008-06-10 | 2012-08-07 | Boston Scientific Scimed, Inc. | Bioerodible endoprosthesis |
| US7985252B2 (en) | 2008-07-30 | 2011-07-26 | Boston Scientific Scimed, Inc. | Bioerodible endoprosthesis |
| US8382824B2 (en) | 2008-10-03 | 2013-02-26 | Boston Scientific Scimed, Inc. | Medical implant having NANO-crystal grains with barrier layers of metal nitrides or fluorides |
| US8389083B2 (en) * | 2008-10-17 | 2013-03-05 | Boston Scientific Scimed, Inc. | Polymer coatings with catalyst for medical devices |
| WO2010101901A2 (en) | 2009-03-02 | 2010-09-10 | Boston Scientific Scimed, Inc. | Self-buffering medical implants |
| US8668732B2 (en) | 2010-03-23 | 2014-03-11 | Boston Scientific Scimed, Inc. | Surface treated bioerodible metal endoprostheses |
| US8895099B2 (en) * | 2010-03-26 | 2014-11-25 | Boston Scientific Scimed, Inc. | Endoprosthesis |
| KR101116673B1 (en) * | 2010-12-13 | 2012-02-22 | 전남대학교병원 | Gene-releasing stent using titanium-oxide coated thin film and method for manufacturing thereof |
| CN106693043B (en) * | 2015-11-18 | 2020-06-16 | 先健科技(深圳)有限公司 | Absorbable iron-based alloy implanted medical instrument and preparation method thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0966979B1 (en) * | 1998-06-25 | 2006-03-08 | Biotronik AG | Implantable bioresorbable support for the vascular walls, in particular coronary stent |
| US6355271B1 (en) * | 1999-02-03 | 2002-03-12 | Biosante Pharmaceuticals, Inc. | Therapeutic calcium phosphate particles and methods of manufacture and use |
| IN192520B (en) * | 2001-08-01 | 2004-04-24 | Univ Delhi | |
| US7247288B2 (en) * | 2002-04-18 | 2007-07-24 | Carnegie Mellon University | Method of manufacturing hydroxyapatite and uses therefor in delivery of nucleic acids |
| US20050084513A1 (en) * | 2003-10-21 | 2005-04-21 | Board Of Regents | Nanocoating for improving biocompatibility of medical implants |
| US20060127442A1 (en) * | 2004-12-09 | 2006-06-15 | Helmus Michael N | Use of supercritical fluids to incorporate biologically active agents into nanoporous medical articles |
| EP2021522A2 (en) * | 2006-04-28 | 2009-02-11 | Biomagnesium Systems Ltd. | Biodegradable magnesium alloys and uses thereof |
-
2007
- 2007-08-30 CA CA002662473A patent/CA2662473A1/en not_active Abandoned
- 2007-08-30 US US11/847,934 patent/US20080057105A1/en not_active Abandoned
- 2007-08-30 WO PCT/US2007/019092 patent/WO2008030383A2/en active Application Filing
- 2007-08-30 JP JP2009527364A patent/JP2010502362A/en not_active Withdrawn
- 2007-08-30 EP EP07837545A patent/EP2068967A2/en not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| WO2008030383A3 (en) | 2009-05-28 |
| EP2068967A2 (en) | 2009-06-17 |
| US20080057105A1 (en) | 2008-03-06 |
| WO2008030383A2 (en) | 2008-03-13 |
| JP2010502362A (en) | 2010-01-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20080057105A1 (en) | Medical devices having nanostructured coating for macromolecule delivery | |
| EP2043700B1 (en) | Medical devices having a temporary radiopaque coating | |
| Wu et al. | Engineering and functionalization of biomaterials via surface modification | |
| Yuan et al. | Antibacterial surface design of biomedical titanium materials for orthopedic applications | |
| Zhang et al. | Advances in coatings on magnesium alloys for cardiovascular stents–a review | |
| Losic et al. | Titania nanotube arrays for local drug delivery: recent advances and perspectives | |
| EP2307070B1 (en) | Medical devices having metal coatings for controlled drug release | |
| JP5693456B2 (en) | Intraluminal medical device and method for manufacturing the same | |
| Chu | Surface engineering and modification of biomaterials | |
| US20080071353A1 (en) | Endoprosthesis containing magnetic induction particles | |
| US20130004560A1 (en) | Polymer Nanofilm Coatings | |
| JP2010534518A (en) | Parts with a ceramic coated surface | |
| Mahmoudi et al. | Antibacterial Ti–Cu implants: A critical review on mechanisms of action | |
| KR20070095916A (en) | Chelating and binding chemicals to a medical implant | |
| Jennings et al. | Chitosan coatings to control release and target tissues for therapeutic delivery | |
| Md Yusop et al. | Modifications on porous absorbable Fe‐based scaffolds for bone applications: A review from corrosion and biocompatibility viewpoints | |
| Pishbin et al. | Bioactive polymer–calcium phosphate composite coatings by electrophoretic deposition | |
| Cheng et al. | Electrophoretic deposition of coatings for local delivery of therapeutic agents | |
| JP4340744B2 (en) | Drug eluting stent | |
| WO2010119443A1 (en) | Process for electrochemical coating of conductive surfaces by organic nanoparticles | |
| Yusop et al. | Drug-device systems based on biodegradable metals for bone applications: Potential, development and challenges | |
| Sidhu et al. | Surface modification of metallic orthopedic implants for anti-pathogenic characteristics | |
| WO2010022226A2 (en) | Medical devices having a coating for electromagnetically-controlled release of therapeutic agents | |
| JP6068921B2 (en) | Manufacturing method of drug eluting device | |
| Singh et al. | Nanomaterials for Antibiofilm Activity |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |
Effective date: 20130830 |
|
| FZDE | Discontinued |
Effective date: 20130830 |